ArticlePloS one2024

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective.

Nimer S Alkhatib et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.